Novartis UK response to the NICE Final Appraisal Determination (FAD) for Aimovig® (erenumab) for the prevention of migraine
Sep 25, 2019
Statement from Haseeb Ahmad, Managing Director UK, Ireland and Nordics, Novartis Pharmaceuticals & Country President UK:
“We’re very disappointed that the National Institute for Health and Care Excellence (NICE) has not recommended Aimovig® (erenumab) for use on the National Health Service (NHS). Clearly this is not the result we’ve been working towards; with chronic migraine patients in England who could benefit from Aimovig being denied routine access to this important treatment option, whilst it is NHS funded in Scotland1.
This decision is particularly disappointing given NICE has recognised the clinical-effectiveness and tolerability of Aimovig in chronic migraine, and there remains an unmet need for effective and well-tolerated preventive migraine treatments in the UK2.
Unlike Botulinum toxin type A (Botox®) which is approved by NICE for chronic migraine3, Aimovig can be self-administered at home and does not require repeated clinic visits or multiple injections into the head and neck. Furthermore, treatment with Botox may not be appropriate for everyone that lives with the devastating impact of chronic migraine.
Novartis has a track record of going above and beyond when it comes to working with reimbursement agencies and we understand the need for companies to be flexible in order to make new medicines readily available. As such, we have been working closely with NICE to come to an agreement on an access scheme for Aimovig. Despite further improving our commercial proposition, within the parameters of the NICE appraisal process, the committee felt there to be remaining uncertainty in the evidence and were therefore unable to give a positive final appraisal determination (FAD) recommendation2.
We believe in the benefits that Aimovig offers, and we appreciate how disappointing this news will be for those who have waited many years for a targeted preventive treatment to be made widely available. We remain committed to supporting the migraine community and will continue to investigate options that could enable access to this much needed medicine.”
# # #
NOTES TO EDITORS
Novartis has a Patient Access Scheme (PAS) in place for Aimovig with a confidential discount offered to the NHS. We believe the PAS price of Aimovig reflects the clinical value it can bring to the patient population outlined in the NICE submission.
We acknowledge that NHS resources are limited and that other preventive migraine treatment options can be tried first. This is why Aimovig was positioned within the NICE submission for migraine patients for whom three or more prior preventive treatments have failed.
Aimovig was accepted by the Scottish Medicines Consortium (SMC) in April 2019, for use within NHS Scotland for the treatment of adults with chronic migraine for whom at least three prior preventive treatments have failed1.